CSPC Pharmaceutical Group Ltd (1093)

9.59
+0.04(+0.42%)
  • Volume:
    31,901,327
  • Bid/Ask:
    9.58/9.59
  • Day's Range:
    9.34 - 9.60

1093 Overview

Prev. Close
9.55
Day's Range
9.34 - 9.6
Revenue
29.82B
Open
9.6
52 wk Range
7.08 - 11.16
EPS
0.51
Volume
31,901,327
Market Cap
114.83B
Dividend (Yield)
0.13 (1.33%)
Average Vol. (3m)
71,385,056
P/E Ratio
18.66
Beta
0.69
1-Year Change
12%
Shares Outstanding
11,973,769,732
Next Earnings Date
May 25, 2021
What is your sentiment on CSPC Pharmaceutical Group Ltd?
or
Market is currently closed. Voting is open during market hours.

CSPC Pharmaceutical Group Ltd News

CSPC Pharmaceutical Group Ltd Analysis

  • How To Invest In The 'Asian Century'

    The 19th century belonged to the United Kingdom, the 20th century to the United States. Many market experts and analysts now speculate that the 21st century will be remembered as...

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyStrong BuyStrong BuySell
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong BuyStrong Sell
SummaryStrong BuyStrong BuyStrong BuyStrong BuyStrong Sell

CSPC Pharmaceutical Group Ltd Company Profile

CSPC Pharmaceutical Group Ltd Company Profile

Employees
17292
Market
Hong Kong

CSPC Pharmaceutical Group Limited is an investment holding company principally engaged in the manufacture and sales of pharmaceutical products. The Company sells its products under the brand of CSPS. The Company has four business segments: Finished Drugs, Antibiotics (intermediates and bulk drugs), Vitamin C (bulk drugs) and Caffeine and Others (bulk drugs). All these segments are engaged in the manufacture and sales of related pharmaceutical products. The finished drugs include the antibiotics, cardio-cerebrovascular drugs, diabetes drugs, neurology drugs, oncology drugs and traditional Chinese medicines. The Company is also engaged in the provision of pharmaceutical research and development services, as well as the processing of sewage and pharmaceutical by-products through its subsidiaries.

Read More
  • Credit Suisse Lifts CSPC PHARMA  TP to $11.5 as Management Guides For Double-digit FY21 Rev. Growth
    0
    • HSBC Global Research Inches Down CSPC PHARMA (1093) TP to $14.3; ***Rated Buy***
      0
      Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
      Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.